Equiscale Logo
Equiscale
NSE / BSEHealthcare
β‚Ή9190.00-136.00-1.46%
P/E67.9Mkt Capβ‚Ή1.71 L CrEV/EBITDA67.2

Divi's Laboratories Ltd.

P/E67.9Mkt Capβ‚Ή1.71 L CrEV/EBITDA67.2
Company Profile

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 15 Sept 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
β€”
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Strengths1

  • Maintains healthy dividend payout of 50.0%

Concerns0

    Rule-based from financial data. Not advice.

    Price Historyβ–² 51.84% over 1Y
    Technical Chart

    Monthly Returns

    Unlock Monthly Returns

    Available on Pro and Institutional plans.

    Sign up free

    Year-to-Date ROI

    Unlock Year-to-Date ROI

    Available on Pro and Institutional plans.

    Sign up free

    Historical Volatility

    Unlock Historical Volatility

    Available on Pro and Institutional plans.

    Sign up free

    Historical Performance

    Revenue, profitability, and cash flow trends (β‚Ή Crores)

    Revenue (10Y)

    Operating Income (10Y)

    Net Profit (10Y)

    Operating Margin % (10Y)

    Dividend Payout % (10Y)

    Free Cash Flow (10Y)

    Growth Summary

    Latest fiscal year: Mar 2025

    Revenueβ‚Ή9.20 K Crβ–² 20.0%
    EBITDA Growthβ€”
    Net Profitβ‚Ή2.21 K Crβ–² 40.2%
    Cash from Ops (CFO)β€”
    Free Cash Flow (FCF)β€”β–Ό 75.0%
    Revenue CAGR 5Y7.6%
    EBITDA CAGR 5Y4.6%
    Net Profit CAGR 5Y2.8%
    NP Growth 1Y40.2%

    Historical Growth

    Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

    YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
    Mar 2025β‚Ή9.20 K Crβ€”β‚Ή2.21 K Crβ€”β€”14.8%20.0%40.2%
    Mar 2024β‚Ή7.67 K Crβ€”β‚Ή1.58 K Crβ€”β€”11.7%0.5%-12.8%
    Mar 2023β‚Ή7.63 K Crβ€”β‚Ή1.81 K Crβ€”β€”14.2%-14.1%-38.7%
    Mar 2022β‚Ή8.88 K Crβ€”β‚Ή2.95 K Crβ€”β€”25.2%30.6%50.8%
    Mar 2021β‚Ή6.80 K Crβ€”β‚Ή1.96 K Crβ€”β€”21.1%28.0%42.4%
    Mar 2020β‚Ή5.31 K Crβ€”β‚Ή1.37 K Crβ€”β€”18.8%8.8%3.0%
    Mar 2019β‚Ή4.88 K Crβ€”β‚Ή1.33 K Crβ€”β€”19.1%27.9%53.2%
    Mar 2018β‚Ή3.82 K Crβ€”β‚Ή870.00 Crβ€”β€”14.6%-5.2%-17.4%
    Mar 2017β‚Ή4.02 K Crβ€”β‚Ή1.05 K Crβ€”β€”19.5%8.2%-5.2%
    Mar 2016β‚Ή3.72 K Crβ€”β‚Ή1.11 K Crβ€”β€”25.5%20.6%31.2%

    Financial Statements

    Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

    Free plan Β· showing 1 year of data.Upgrade

    Consolidated Figures in USD Millions.

    Unnamed: 0TTM
    Revenue / Net Sales9,850
    Total Expenses6,584
    EBIT / Operating Profit3,266
    OPM %33%
    Other Income434
    Finance Costs11
    Depreciation & Amortisation431
    Profit Before Tax3,258
    Tax %-
    Net Profit / PAT2,514
    EPS (β‚Ή)94.71
    Dividend Payout %-

    Peer Comparison

    Healthcare sector peers, ranked by market cap

    CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
    Divi's Laboratories Ltd.this co.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
    Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
    Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
    Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
    Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
    Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
    Lupin Ltdβ‚Ή99.47 K Crβ‚Ή16.97 K Cr18.603.6627.4315.7%
    Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

    Learn while you research

    Hand-picked academy chapters to deepen your understanding of Divi's Laboratories Ltd. and the metrics that matter.

    01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read03 Valuation Multiples ExplainedThis stock trades at a P/E of 67.9, learn when high multiples are justified.6 min read04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read

    Key concepts to brush up on

    P/E RatioP/B RatioROEROCEFree Cash FlowDebt / EquityLTCG Tax
    Browse the full Equiscale Academy